What NextPoint Therapeutics does

NextPoint Therapeutics is a clinical-stage biotechnology company developing first-in-class precision immuno-oncology therapeutics that target the B7-H7 (HHLA2) immune checkpoint pathway. The company is based in Cambridge, Massachusetts and was built on the foundational discoveries of scientific co-founders Gordon Freeman, PhD (Dana-Farber Cancer Institute; discoverer of PD-L1) and XingXing Zang, PhD (Albert Einstein College of Medicine; discoverer of HHLA2, B7x, and TMIGD2). Its stated thesis is that B7-H7 represents a non-redundant, tumor-restricted immune evasion pathway that operates independently of PD-L1, enabling treatment of solid tumor patients who do not benefit from approved PD-1/L1 inhibitors.

The pipeline comprises four programs across three therapeutic modalities, each engineered around the B7-H7 axis: NPX887, a tri-functional B7-H7 checkpoint inhibitor that blocks the inhibitory B7-H7/KIR3DL3 interaction, enhances co-stimulation via TMIGD2, and drives ADCC-mediated tumor killing (Phase 1 in EGFR-mutant NSCLC and HHLA2+ solid tumors); NPX372, a 2:1 B7-H7 x CD3 bispecific T-cell engager with an inactivated Fc and target-expression-dependent cytotoxicity (FDA IND clearance received February 2026); NPX125, a B7-H7-targeted antibody-drug conjugate with DAR8 stoichiometry and the proprietary Novatecan linker-payload (IND planned mid-2026); and NPX267, an early KIR3DL3-targeting program now superseded by the newer pipeline assets. Patient selection across all programs is biomarker-driven, leveraging the tumor-restricted expression profile of B7-H7.

NextPoint is pre-revenue and operates a licensing-and-partnership-oriented business model. Capital is sourced from venture and strategic investors, with $122.5M raised in cumulative Series B financing ($80M in January 2023 co-led by Leaps by Bayer and Sanofi Ventures, plus a $42.5M extension in February 2024 led by Catalio Capital Management). The commercial team is built to execute multi-program clinical development and position assets for future out-licensing, co-development, or acquisition by larger pharmaceutical companies; no commercial products are currently marketed and no payer or distribution relationships are disclosed.

Name

NextPoint Therapeutics

Legal name

NextPoint Therapeutics, Inc.

Website

https://nextpointtx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

NextPoint Therapeutics is a clinical-stage biotech developing first-in-class immuno-oncology therapeutics that target the B7-H7 (HHLA2) immune checkpoint pathway for solid tumor patients unresponsive to PD-1/L1 inhibitors. Its pipeline spans T-cell engagers, ADCs, and checkpoint inhibitors.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Immuno-oncology therapeutics
• Precision oncology
• Antibody-drug conjugates
• T-cell engagers
• Cancer immunotherapy

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Licensing: As a clinical-stage biotech company, NextPoint Therapeutics develops novel immuno-oncology therapeutics targeting the B7-H7 pathway. The company's revenue model is based on developing proprietary drug candidates through clinical trials with the intent to commercialize through licensing agreements, co-development partnerships, or acquisition by larger pharmaceutical companies. The company is pre-revenue with multiple programs in clinical development.

Go-to-market motion1 record

Marketing channels4 records

Core offering

NextPoint Therapeutics is a clinical-stage biotechnology company developing first-in-class precision immuno-oncology therapeutics targeting the B7-H7/HHLA2 immune checkpoint pathway. Its pipeline includes NPX372 (2:1 bispecific T-cell engager), NPX125 (DAR8 antibody-drug conjugate with proprietary Novatecan linker), and NPX887 (tri-functional checkpoint inhibitor), each designed to treat solid tumors unresponsive to approved PD-1/L1 inhibitors through biomarker-driven patient selection.

Product overview

NextPoint Therapeutics is advancing a unified pipeline of first-in-class precision oncology therapeutics targeting the B7-H7 (HHLA2) pathway. The portfolio includes three core modalities: NPX372 (a 2:1 bispecific T cell engager), NPX125 (an antibody-drug conjugate with proprietary linker technology), and NPX887 (a tri-functional checkpoint inhibitor). All programs combine direct tumor cell killing with immunomodulation in single molecules, guided by a validated biomarker strategy to identify patients most likely to benefit. The company focuses on cancers unresponsive to existing PD-1/L1 inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

• NPX372 First-in-class 2:1 bispecific T-cell engager (TCE) targeting B7-H7 with CD3, engineered with an inactivated Fc region, low non-specific cytokine induction, and target expression-dependent cytotoxicity. Purpose-built for a wide therapeutic window in solid tumor treatment; preclinical studies demonstrated complete tumor regression with favorable tolerability and no evidence of cytokine release syndrome.
• NPX125 B7-H7 targeted antibody-drug conjugate (ADC) with DAR8 optimized for tumor payload delivery via Novatecan, the company's proprietary linker-payload technology. Leverages B7-H7's internalization profile and tumor-specific expression for direct tumor killing; in vivo studies demonstrated complete responses across a range of tumor models.
• NPX887 Tri-functional B7-H7 checkpoint inhibitor designed to block the inhibitory B7-H7/KIR3DL3 interaction, enhance co-stimulation via TMIGD2, and drive ADCC-mediated tumor killing. In Phase 1 clinical development for B7-H7-positive solid tumors.
• NPX267 Therapeutic targeting KIR3DL3 designed to reactivate exhausted T and NK cells in HHLA2+ solid tumors; the company's first clinical-stage program entering Phase 1a/b trials.

Quantifiable outcome

• Complete tumor regression demonstrated in preclinical studies for NPX372 (T-cell engager) in multiple solid tumor models
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerScientific founder Gordon Freeman, PhD is from the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. His foundational research on B7 family immune checkpoint pathways forms the basis of the company's technology. Leena Gandhi, Chief Medical Officer, was previously faculty at Dana-Farber.
• Albert Einstein College of MedicinecoreStrategic or Co-development PartnerScientific founder XingXing Zang, PhD is Professor and founding Director of Institute for Immunotherapy at Albert Einstein College of Medicine, New York. His discoveries of B7x, HHLA2, TMIGD2, and related pathways form the scientific foundation for the company's therapeutic approach.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NextPointTX
• LinkedInlinkedin.com/company/nextpoint-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NextPoint Therapeutics